Clinical Trial Update: A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 trial evaluated the safety and preliminary efficacy of SGN-30 (brentuximab vedotin) in patients with CD30-positive Hodgkin lymphoma and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma
• Kaposi Sarcoma

Drugs mentioned

• SGN-30 (brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Hodgkin Disease, Lymphoma, Large-Cell | Phase 1, Phase 2 | Status: COMPLETED